UA138843U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of methylenetetrahydrofolate reductase genes (MTHFR C677T), nitric oxide synthase (eNOS T786C), the content of endothelin, transforming growth factor beta 1 (TGF-b1), C-reactive 6P protein ), homocysteine. With a homozygous carrier of 677-TT, 786-CC and endothelin levels> 10 ng / ml, TGF-b1 <14 ng / ml, PSA> 6 mg / l, IL-6> 10 ng / l, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

The proposed useful model, a method of predicting the development of osteoarthritis, belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The set task is solved by the fact that, in addition to clinical examination and radiography, polymorphism of methylenetetrahydrofolate reductase genes (MTNEV) is determined in the patient's blood serum

C677T), nitric oxide synthase (EEMO5 T786C), content of endothelin, transforming growth factor beta 1 (TGF-DVI), C-reactive protein (CRP), interleukin 6 (IL-6), homocysteine. With homozygous carriers of 677-TT, 786-SS, levels of endothelin 210 ng/ml, TFR-B1 "14 ng/ml, SRP "6 mg/l, IL-6 210 ng/l, homocysteine 220 μmol/l predict the development of osteoarthritis .

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the polymorphism of MTNEV C677T, eMmo5 T786C genes is determined, the content of endothelin, TFR-B1I, SRP, IL-6, and homocysteine is determined by the immunoenzymatic method. With homozygous carrier 677-1T, 786-SS, levels of endothelin 210 ng/ml, TFR-B1 "14 ng/ml, SRP "6 mg/l, IL-b6 "10 ng/l, homocysteine 220 μmol/l predict the development osteoarthritis

A specific example of using the method.

Patient M., 62 years old, was hospitalized in the clinic due to pain syndrome in the right knee joint. Examined, x-ray taken. No signs of osteoarthritis were found. The polymorphism of MTNEV C677T and eMmo5 17860 genes was determined in blood serum. The content of endothelin, TFR-VI, SRP, IL-b6, and homocysteine was determined by immunoenzymatic method. A homozygous carrier of 677-117 and 786-SS was established, endothelin levels - 20 ng/ml, TGF-β1 - 8.2 ng/ml, PSA - 14 mg/l, IL-6 - 22 ng/l, homocysteine - 40 μmol / l. The development of osteoarthritis was diagnosed. By

From 12 months on, X-rays showed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that in the patient's blood serum polymorphisms of the genes methylenetetrahydrofolate reductase (MTNEV C677T), nitric oxide synthase (EMO5 1786С), the content of endothelin, transforming growth factor beta 1 (TGF- RI), C-reactive protein (SRP), interleukin b (IL-6), homocysteine and with homozygous carrier 677-GTT, 786-SS and endothelin levels 210 ng/ml, TFR-DI "14 ng/ml, SRP "b6 mg/l, IL-b6 "10 ng /l, homocysteine 220 μmol/l predict the development of osteoarthritis.